Impax Laboratories IPXL

May 1 (Reuters) - Specialty pharmaceutical company Impax Laboratories Inc's quarterly profit beat analysts expectations as sales of its generic versions of attention deficit hyperactivity disorder drug Adderall rose nearly 50 percent.

Impax Laboratories ( IPXL ): Q1 EPS of $0.52 beats by $0.07 . Revenue of $123.3M (+18.3% Y/Y) misses by $40M . ( PR ) Post your comment!

By StockPandit : Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch. However, my focus is on biotechnology and drugs stocks that have earnings due in the next week. This article provides earnings previews on several stocks to consider

By Kapitall : Do you value companies holding large amounts of cash? For a closer look at highly liquid names, we ran a screen on the healthcare sector. We began by screening U.S.-traded healthcare stocks for those with significant liquidity, with current ratios above 3. Since the current ratio is

DepoMed ( DEPO ) files a lawsuit againt Impax Laboratories ( IPXL ) and Par Pharmaceutical ( PRX ) for patent infringement covering ANDAs filed by the firms to market generic versions of Gralise …

By Kapitall : The healthcare sector is generally considered a growth sector, primarily because it includes the biotech industry. However some healthcare names exhibit value company characteristics such as large dividends. For a closer look into healthcare, we ran a screen. We began by screening for

Feb 28 (Reuters) - Impax Laboratories Inc's quarterly profit rose 76 percent, driven by growth at key pharmaceuticals and generics divisions.

Impax Laboratories ( IPXL ): Q4 EPS of $0.33 beats by $0.14 . Revenue of $159M (+60% Y/Y) beats by $30M . ( PR ) Post your comment!